IMPROVED QUALITY OF LIFE IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS FOLLOWING 24 WEEKS OF TREATMENT WITH ODEVIXIBAT, AN ILEAL BILE ACID TRANSPORTER INHIBITOR: RESULTS FROM THE PHASE 3 PEDFIC 1 STUDY

被引：0
|
作者：
Thompson, R. J. [1 ]
Kjems, L. [2 ]
Hardikar, W. [3 ]
Lainka, E. [4 ]
Calvo, P. L. [5 ]
Horn, P. [2 ]
机构：
[1] Kings Coll London, Inst Liver Studies, London, England
[2] Albireo Pharma Inc, Boston, MA USA
[3] Royal Childrens Hosp, Melbourne, Vic, Australia
[4] Univ Duisburg Essen, Childrens Hosp, Dept Pediat Gastroenterol Hepatol & Transplant Me, Essen, Germany
[5] Azienda Osped Citta Salute & Sci Torino, Regina Margherita Childrens Hosp, Pediat Gastroenterol Unit, Turin, Italy
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMU62
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 8 条
  • [1] EFFECTS ON SERUM BILE ACIDS, PRURITUS, AND SAFETY WITH UP TO 72 WEEKS OF ODEVIXIBAT TREATMENT: POOLED DATA FROM THE PEDFIC 1 AND PEDFIC 2 STUDIES IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
    Loomes, Kathleen M.
    Verkade, Henkjan J.
    Thompson, Richard J.
    Kamath, Binita
    Hardikar, Winita
    Lacaille, Florence
    Mozer-Glassberg, Yael
    Shteyer, Eyal
    Calvo, Pier Luigi
    Dalgic, Buket
    Grammatikopoulos, Tassos
    Rajwal, Sanjay
    Vittorio, Jennifer M.
    Soufi, Nisreen
    McKiernan, Patrick James
    Tessier, Mary Elizabeth
    Yu, Qifeng
    Kjems, Lise
    Horn, Patrick
    HEPATOLOGY, 2021, 74 : 1159A - 1160A
  • [2] Pretreatment serum bile acid parameters and predictability of response to odevixibat, an ileal bile acid transport inhibitor, in children with progressive familial intrahepatic cholestasis
    Verkade, Henkjan
    Kuipers, Folkert
    Ni, Quanhong
    Valcheva, Velichka
    Horn, Patrick
    Mattsson, Jan
    Gillberg, Per-Goran
    Kjems, Lise
    JOURNAL OF HEPATOLOGY, 2021, 75 : S688 - S689
  • [3] HEPATIC PARAMETERS, GROWTH, AND SLEEP WITH RESPONDERS AND NONRESPONDERS TO ODEVIXIBAT TREATMENT: POOLED DATA FROM THE PEDFIC 1 AND PEDFIC 2 STUDIES IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
    McKiernan, Patrick James
    Sturm, Ekkehard
    Kamath, Binita
    Thompson, Richard J.
    Gonzales, Emmanuel M.
    Lachaux, Alain
    Baumann, Ulrich
    Shteyer, Eyal
    Czubkowski, Piotr
    Artan, Reha
    Dalgic, Buket
    Ozen, Hasan
    Gupte, Girish
    Grammatikopoulos, Tassos
    Karpen, Saul J.
    Ni, Quanhong
    Kjems, Lise
    Horn, Patrick
    HEPATOLOGY, 2021, 74 : 1164A - 1164A
  • [4] NATURAL VARIATION OF SERUM BILE ACID LEVELS AND PRURITUS IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: PRETREATMENT DATA FROM PATIENTS IN THE PHASE 3 PEDFIC 1 STUDY
    Verkade, Henkjan J.
    Kuipers, Folkert
    Yu, Qifeng
    Valcheva, Velichka
    Horn, Patrick
    Kjems, Lise
    HEPATOLOGY, 2021, 74 : 1171A - 1172A
  • [5] LONG-TERM TREATMENT WITH ODEVIXIBAT IMPROVES MULTIPLE SLEEP PARAMETERS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: A POOLED RESPONDER ANALYSIS FROM THE PHASE 3 PEDFIC STUDIES
    Thompson, Richard J.
    Calvo, Pier Luigi
    Hardikar, Winita
    Horn, Patrick
    Lainka, Elke
    Mack, Cara L.
    Ni, Quanhong
    Kjems, Lise
    GASTROENTEROLOGY, 2022, 162 (07) : S1297 - S1297
  • [6] Long-term treatment with odevixibat improves multiple sleep parameters in patients with progressive familial intrahepatic cholestasis: a pooled responder analysis from the phase 3 PEDFIC studies
    Thompson, Richard
    Calvo, Pier Luigi
    Hardikar, Winita
    Horn, Patrick
    Lainka, Elke
    Mack, Cara
    Ni, Quanhong
    Kjems, Lise
    JOURNAL OF HEPATOLOGY, 2021, 75 : S683 - S684
  • [7] Substantial clinical benefits with odevixibat treatment across progressive familial intrahepatic cholestasis genetic deficiencies: subgroup analysis of serum bile acids, pruritus, and safety using pooled data from the PEDFIC 1 and 2 studies
    Thompson, Richard
    Horn, Patrick
    Houwen, Roderick H. J.
    Lacaille, Florence
    Ni, Quanhong
    Stein, Philip
    Tessier, Mary Elizabeth
    Thompson, Carrie
    Vittorio, Jennifer
    Kjems, Lise
    JOURNAL OF HEPATOLOGY, 2021, 75 : S684 - S685
  • [8] Phase 2 open-label efficacy and safety study of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with progressive familial intrahepatic cholestasis: 48-week interim efficacy analysis
    Thompson, Richard J.
    Kelly, Deirdre A.
    McClean, Patricia
    Miethke, Alexander G.
    Soufi, Nisreen
    Rivet, Christine
    Jankowska, Irena
    Mack, Cara L.
    Karthikeyan, Palaniswamy
    Gu, Joan
    Jaecklin, Thomas
    Squires, Robert H.
    Loomes, Kathleen M.
    HEPATOLOGY, 2017, 66 : 57A - 57A
1